Onfi Approval Shows Benefits Of Lundbeck's Ovation Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Clobazam is approved as an add-on to therapy for a particularly severe orphan seizure disorder known as Lennox-Gastaut syndrome.
You may also be interested in...
Lundbeck Onfi Gets Dermatological Warning, Bigger Marketing Challenge
Labeling for Eisai’s Banzel, which also has an indication limited to Lennox-Gastaut syndrome, does not mention Stevens-Johnson syndrome or toxic epidermal necrolysis cited in the Onfi warning.
Lundbeck Invests £10M In CNS-Focused Proximagen
Lundbeck's support for Proximagen comes as biotechs struggle for survival in the high-risk CNS space.
MDD Market Snapshot: Depressing Future For Antidepressants
Although a significant portion of the U.S. population – approximately 6.5% or 15 million adults annually – suffers from depression, the antidepressant drug market is on the decline and sales are expected to decrease further over the next two years as two of the largest products on the market, Forest Laboratories’ Lexapro (escitalopram) and Eli Lilly & Co.’s Cymbalta (duloxetine), face patent expirations.